ReviewGenes & diseases2026
Defective biological networks associated with pseudogene-derived lncRNAs in cancer drug resistance: Promising prospects for their clinical targets in cancer therapy.
Review in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a major cause of mortality globally, characterized by its multifactorial nature and intricate treatment procedures. The main treatment options include targeted drug therapies and chemotherapy. However, overcoming drug resistance remains a significant challenge in curing cancer patients. In recent decades, substantial efforts have been made to explore the resistance of cancer cells to anti-cancer agents and to create methods to counteract this resistance. Cancer cell resistance can be attributed to various factors, including long non-coding RNAs (lncRNAs) involved in cell cycle dysregulation, abnormal DNA repair, cell proliferation, epithelial-mesenchymal transition, metastasis, apoptosis, autophagy, drug efflux transporters, epigenetic modifications, and the formation of cancer stem cells. Pseudogenes are genomic regions that harbor impaired or dysfunctional versions of genes. Although pseudogenes were traditionally considered non-functional, a growing number of them are now being found to serve important biological functions. Recent research has demonstrated that mutations and dysregulation of pseudogene-derived lncRNAs are linked with various human diseases, such as cancer drug resistance. This review concentrates on exploring the latest discoveries that elucidate the diverse molecular functions of regulatory pseudogene-derived lncRNAs implicated in cancer drug resistance and the therapeutic possibilities for overcoming drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.